# Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

> **NCT07058103** · PHASE2 · RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Angioimmunoblastic T-Cell Lymphoma Recurrent
- Angioimmunoblastic T-Cell Lymphoma Refractory

## Interventions

- **DRUG:** tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone

## Key facts

- **NCT ID:** NCT07058103
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07058103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07058103, "Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07058103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*